Entity

Time filter

Source Type

Xianshuigu, China

Zhao H.-L.,Jinnan Xianshuigu Hospital
Chinese Journal of Tissue Engineering Research | Year: 2015

BACKGROUND: Human telomerase reverse transcriptase (hTERT) is the first choice for regulating the proliferation and directional differentiation, with multiple biological effects. OBJECTIVE: To observe the therapeutic effect of hTERT-transfected bone marrow mesenchymal stem cells transplantation in diabetic rats. METHODS: Bone marrow mesenchymal stem cells from Sprague-Dawley rats were cultured in vitro and transfected with retrovirus PLXSN carrying hTERT. RT-PCR was used to detect the hTERT expression in the bone marrow mesenchymal stem cells before and after transfection. Sixty male Sprague-Dawley rats were selected and equally randomized into four groups: normal control group, transfection group, cell transplantation group, and model group. In the latter three groups, rats were injected with 45 mg/kg chain urea to establish diabetes models, and then injected via the tail vein with 0.2 mL hTERT-transfected bone marrow mesenchymal stem cells, 0.2 mL bone marrow mesenchymal stem cells, and 0.2 mL normal saline, respectively. RESULTS AND CONCLUSION: At 48 hours after hTERT transfection, the expression of hTERT mRNA was detected in the bone marrow mesenchymal stem cells, and mainly concentrated in the nuclei. At 14 days after transfection, the fasting glucose level in the model group was higher than that in the normal control group (P < 0.05). However, compared with the model group, the fasting glucose levels in the transfection and cell transplantation groups were significantly decreased (P < 0.05); compared with the cell transplantation group, the fasting glucose level in the transfection group was also significantly decreased (P < 0.05), which was similar to that in the normal control group (P > 0.05). These findings indicate that the transplantation of hTERT-transfected bone marrow mesenchymal stem cells is effective in the treatment of diabetic rats. © 2015 Journal of Clinical Rehabilitative Tissue Engineering Research. All rights reserved. Source


Xu Y.,Jinnan Xianshuigu Hospital
Chinese Journal of Tissue Engineering Research | Year: 2015

BACKGROUND: To protect the pulmonary vascular endothelial cells in the body is an important part to reduce pulmonary circulation pressure and prevent pulmonary hypertension. OBJECTIVE: To observe the therapeutic efficacy of umbilical cord blood mesenchymal stem cell transplantation carrying human telomerase reverse transcriptase (hTERT) in the treatment of pulmonary hypertension in rats. METHODS: Umbilical cord blood mesenchymal stem cells were cultured, purified and transfected with adenovirus carrying hTERT gene. Sixty Sprague-Dawley male rats were randomly divided into model group, blank adenovirus group, adenoviral delivery group, with 20 rats in each group. Then, the rats were respectively injected via the jugular vein with 1 mL L-DBEB, 1 mL umbilical cord blood mesenchymal stem cell suspension (1.5×1010/L), and 1 mL hTERT-transfected umbilical cord blood mesenchymal stem cell suspension (1.5×1010/L) after models of pulmonary hypertension were established via intraperitoneal injection of monocrotaline. After 21 days of transplantation, hemodynamic changes, plasma endothelin 1 levels and the hypertrophy index of the right ventricle were detected. RESULTS AND CONCLUSION: There was no difference in arterial blood pressure among the three groups (P < 0.05). In the adenoviral delivery group, the systolic pressure of the pulmonary artery, mean pulmonary artery pressure and plasma endothelin 1 level decreased significantly as compared with the model group, blank adenovirus group (P < 0.05); but no difference was found in the hypertrophy index of the right ventricle (P > 0.05). These findings indicate that umbilical cord blood mesenchymal stem cell transplantation carrying hTERT gene can improve the hemodynamic abnormalities in the body and also protect vascular endothelial cells in the body. © 2015 Journal of Clinical Rehabilitative Tissue Engineering Research. All rights reserved. Source


BACKGROUND: The repair effects of bone marrow mesenchymal stem cell transplantation on brain injury were not ideal. Combined therapy with medicine and biological engineering materials is needed. OBJECTIVE: To investigate the effects of bone marrow mesenchymal stem cell transplantation and fingolimod immunosuppressants on memory function recovery in rats with brain injury. METHODS: A total of 60 healthy Sprague-Dawley rats were subjected to hydraulic shock with peak value of 253.312 5-303.975 kPa with a hydraulic head injury instrument so as to induce a model of severe hydraulic head injury. They were randomly divided into brain injury group, bone marrow mesenchymal stem cell transplantation group and fingolimod + bone marrow mesenchymal stem cell transplantation group. The Morris water maze test was tested at 21-28 days after PKH-26-labeled bone marrow mesenchymal stem cell transplantation. The PKH-26 immunofluorescence and hematoxylin-eosin staining were conducted in brain tissues at 4 weeks after brain injury. RESULTS AND CONCLUSION: At 4 weeks after transplantation, the average escape latency was gradually decreased in each group. The average escape latency was shorter in the fingolimod + bone marrow mesenchymal stem cell transplantation group than in the bone marrow mesenchymal stem cell transplantation group (P < 0.05), and significantly shorter than in the brain injury group (P < 0.01). The number of times of crossing the platform and the percentage of swimming distance to total distance were higher in the fingolimod + bone marrow mesenchymal stem cell transplantation group than in the brain injury group and bone marrow mesenchymal stem cell transplantation group (P < 0.05). The number of PKH-26-positive cells was significantly higher in the fingolimod + bone marrow mesenchymal stem cell transplantation group than in the brain injury group and bone marrow mesenchymal stem cell transplantation group (P < 0.05). Results confirmed that bone marrow mesenchymal stem cell transplantation could apparently improve memory function of rats with severe brain injury. The combined application of fingolimod immunosuppressants has synergistic effects. Source

Discover hidden collaborations